The underlying cause of LCHADD retinopathy is not fully understood. This presentation will look at the research that identifies the cell in the eye that is initially affected and characteristics associated with vision loss. Join Dr. Gillingham as she discusses early data on the natural history study and some new pre-clinical models to test novel treatments for LCHADD retinopathy.
Join MitoAction and Annette Hines on April 3, 2020 for our April Monthly Mito Expert Series. Ins and Outs of Social Security Navigating Supplemental...
Update by Cristy Balcells about ways to get involved and spread awareness.
Greg Macpherson, CEO of MitoQ, discusses “Mitochondria and MitoQ: A Research Update.” MitoQ’s mission is to raise awareness of mitochondria and the link between...
